Clinical Trials Logo

Insulin Resistance clinical trials

View clinical trials related to Insulin Resistance.

Filter by:

NCT ID: NCT01737658 Completed - Obesity Clinical Trials

Insulin Resistance and Cognitive Dysfunction in Obese Adolescents: Pilot Study

Start date: December 2012
Phase: N/A
Study type: Interventional

Obese Adolescents will be evaluated for insulin resistance and cognitive dysfunction.

NCT ID: NCT01736202 Completed - Insulin Sensitivity Clinical Trials

Acute Effects of an Oral Fat Load on Skeletal Muscle and Hepatic Insulin Sensitivity

FLAME
Start date: March 2012
Phase: Phase 4
Study type: Interventional

The development of type 2 diabetes is based on a combination of insulin resistance and beta cell dysfunction. In the last years, elevated FFA were recognized as a key players in the pathogenesis of insulin resistance and type 2 diabetes. The study compares the acute effects of an oral lipid bolus on insulin sensitivity and hepatic glucose metabolism in healthy humans.

NCT ID: NCT01729403 Completed - Clinical trials for Diabetes Mellitus Type 2

A Study of The Effect of Aleglitazar on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin

Start date: December 2012
Phase: Phase 2
Study type: Interventional

This single-center, randomized, double-blind, placebo-controlled study will evaluate the effect of aleglitazar on insulin sensitivity in patients with type 2 diabetes mellitus who are inadequately controlled on metformin monotherapy. Patients will be randomized to receive either aleglitazar 150 mcg or placebo orally daily for 16 weeks, in addition to their existing dose and regimen of metformin.

NCT ID: NCT01726491 Completed - Obesity Clinical Trials

Epigenetics and the Origin of Muscle Insulin Resistance in Humans

Start date: August 2012
Phase: N/A
Study type: Observational

The investigators are trying to understand the role of DNA (deoxyribonucleic acid) methylation in insulin resistance in skeletal muscle and blood tissues. DNA methylation is a normal chemical process in the body that modifies DNA. By studying this, the investigators hope to better understand the causes of insulin resistance.

NCT ID: NCT01718392 Completed - Multiple Sclerosis Clinical Trials

Rehabilitation in Multiple Sclerosis: Influence of Exercise on Development of Insulin Resistance, Muscle Power and Aerobic Capacity

Start date: March 2011
Phase: N/A
Study type: Interventional

the purpose of this study is to investigate the development of insulin resistance in multiple sclerosis patients + explaining the effects of a combined training programme on insulin resistance, muscle power and aerobic capacity in multiple sclerosis patients

NCT ID: NCT01714102 Completed - Obesity Clinical Trials

Resveratrol and the Metabolic Syndrome

Start date: October 2012
Phase: N/A
Study type: Interventional

Metabolic syndrome is a serious health condition that affects about 35 percent of adults and places them at higher risk of cardiovascular disease, diabetes, stroke and diseases related to fatty buildups in artery walls. The underlying causes of metabolic syndrome are obesity, being overweight, physical inactivity and genetic factors. In recent decades, the prevalence has increased dramatically in the United States. Lifestyle interventions including dietary modification, physical activity and weight loss form the basis of treatment for these patients. However, research has shown that even when people are able to incorporate these changes, they often revert back to their usual lifestyle resulting in weight gain and continued risk for diabetes and heart disease. Resveratrol, a natural plant derived compound found in grapes, peanuts and red wine, has been found to reverse some of the features of the metabolic syndrome (insulin resistance, high triglycerides, high blood pressure) in rodents. These improvements occurred without weight loss, and were proven to be a direct result of resveratrol ingestion. Other studies reveal improvement in cardiovascular health, tumor suppression, and longevity. However, there are few studies investigating these beneficial effects in humans. Investigators propose to prove that resveratrol, administered to subjects with the metabolic syndrome, under controlled conditions of weight stability, common diet, and strict compliance with the study drug, will improve the symptoms of the metabolic syndrome, thereby decreasing the chance of developing diabetes or heart disease.

NCT ID: NCT01690091 Completed - Insulin Resistance Clinical Trials

Cardioprotective and Metabolic Effects of Metformin in Patients With Heart Failure and Diabetes

CARMET
Start date: November 2012
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of the study is to evaluate the effect of metformin on myocardial function, insulin resistance and selected metabolic markers in patients with type 2 diabetes and heart failure (HF+DM+) in a cross-over, randomized, placebo controlled trial. Hypothesis: Metformin treatment in HF+DM+ group will lead to better myocardial function and load tolerance in comparison to placebo. The degree of improvement will be linked to selected metabolic parameters.

NCT ID: NCT01686828 Completed - Obesity Clinical Trials

T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin

T-IR
Start date: June 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this research study is to understand the effects of testosterone and estrogen on the body's response to the hormone insulin.

NCT ID: NCT01686815 Completed - Schizophrenia Clinical Trials

Cross-Sectional Iloperidone IVGTT

Start date: October 2012
Phase:
Study type: Observational

This study aims to utilize state of the art procedures such as the frequently sampled intravenous glucose tolerance test (FSIVGTT), Bergman's Minimal Model Analysis, lipoprotein analysis, and DEXA scans to demonstrate that a newer agent, iloperidone, is devoid of the metabolic abnormalities associated with other atypical antipsychotic treatments, namely olanzapine and risperidone, and offers an advantage over these other agents.

NCT ID: NCT01686568 Completed - Insulin Resistance Clinical Trials

Omega-3 Fatty Acids and Insulin Sensitivity

Start date: December 2012
Phase: Phase 3
Study type: Interventional

This study is being done to understand the effects of dietary omega-3 fats on insulin sensitivity in adult men and women.